Veterinary Animal Vaccines

Veterinary Animal Vaccines Market Outlook

The global veterinary animal vaccines market is projected to reach USD 8.3 billion by 2035, with a compound annual growth rate (CAGR) of 6.2% from 2025 to 2035. The growth of the market can be attributed to several factors including the increasing prevalence of zoonotic diseases, rising awareness about animal health, and a growing demand for safe and effective vaccines among pet owners and livestock farmers. Additionally, advancements in vaccine technology and the rising trend of companion animal ownership globally are also driving the market growth. Furthermore, government regulations aimed at improving food safety and animal welfare are expected to boost the veterinary vaccines market as stakeholders adapt to meet compliance requirements.

Growth Factor of the Market

One of the primary growth factors of the veterinary animal vaccines market is the increasing concern over zoonotic diseases, which can be transmitted from animals to humans. As urbanization accelerates and human-animal interactions increase, the risk of such diseases has been highlighted, leading to a surge in vaccination initiatives for both livestock and companion animals. Additionally, the rise in livestock production, driven by the growing global population and increasing demand for animal protein, necessitates the use of effective vaccination programs to maintain herd health and productivity. Coupled with this, advancements in genetic engineering technologies have paved the way for the development of more effective and specific vaccines, further encouraging their adoption across various animal husbandry practices. The proactive approach adopted by veterinary health professionals emphasizes the importance of regular vaccination, thus reinforcing the market growth. Moreover, increased disposable income among pet owners in emerging economies is fostering a greater willingness to spend on preventative health measures, including vaccines, which contributes to the overall growth of the veterinary animal vaccines market.

Key Highlights of the Market

• The market is anticipated to grow significantly due to increasing awareness of animal health and welfare among pet owners.
• Technological advancements in vaccine development are expected to enhance the efficacy and safety of vaccines.
• Regulatory support for vaccines aimed at controlling zoonotic diseases is contributing to market growth.
• The rise of online pharmacies provides greater access to veterinary vaccines, particularly in remote areas.
• Innovative distribution channels are emerging, improving the availability of vaccines in developing regions.

By Product Type

Inactivated Vaccines:

Inactivated vaccines are developed using pathogens that have been killed or inactivated so that they can no longer cause disease. These vaccines stimulate an immune response without causing the disease itself, making them a safe choice for both livestock and companion animals. The demand for inactivated vaccines is substantial due to their proven history of effectiveness and safety, particularly in large animal populations. They are commonly employed in vaccination programs for diseases such as rabies, foot-and-mouth disease, and other viral infections. The increasing emphasis on disease control in livestock farming, coupled with stringent regulations surrounding animal health, is driving the demand for inactivated vaccines across the globe.

Live Attenuated Vaccines:

Live attenuated vaccines are made from pathogens that have been weakened under laboratory conditions to ensure they do not cause disease in healthy animals. These types of vaccines tend to provoke a strong immune response, making them highly effective. They are widely used in the vaccination of both companion and livestock animals for diseases such as bovine viral diarrhea and Canine Parvovirus. The growing trend of immunizing pets and livestock to prevent outbreaks of disease is significantly boosting the market for live attenuated vaccines. Additionally, their ability to provide long-lasting immunity with fewer doses compared to inactivated vaccines is proving beneficial in veterinary applications.

Recombinant Vaccines:

Recombinant vaccines represent a cutting-edge technology in the veterinary vaccines market, wherein genetic engineering is utilized to produce a portion of the pathogen's genetic material that elicits an immune response. This innovative approach is particularly advantageous as it allows for the development of targeted vaccines that can confer protection against specific diseases without the risk of infection from the whole organism. The increasing adoption of recombinant vaccines in veterinary medicine is largely due to their safety profile and efficacy. They are being extensively used in controlling diseases in various livestock species, thus contributing to the overall health of the agricultural sector. The ongoing research and development in this area are expected to further enhance the range and effectiveness of recombinant vaccines, making them a preferred choice among veterinarians.

DNA Vaccines:

DNA vaccines are a relatively new technology that involves injecting a small, circular piece of DNA (plasmid) that encodes the antigen of the disease-causing organism. This innovative method has shown promising results in various animal species, including fish and livestock. With several advantages, including stability and ease of production, DNA vaccines are gaining traction in the veterinary market. They offer the potential for rapid development and are not affected by the pathogen's mutations. The application of DNA vaccines in controlling diseases such as West Nile Virus in horses and other equine diseases is fostering their acceptance among veterinarians and animal owners. As research continues to explore their effectiveness, the market for DNA vaccines is expected to expand significantly.

Toxoid Vaccines:

Toxoid vaccines are formulated from inactivated toxic compounds produced by pathogens rather than the pathogens themselves. These vaccines are particularly effective against diseases caused by bacterial toxins, such as tetanus and botulism. The use of toxoid vaccines in veterinary medicine is crucial for preventing disease and ensuring animal welfare. The growing awareness of the benefits of toxoid vaccination, along with recommendations from veterinary associations, is leading to increased adoption among livestock and companion animal owners. As animal husbandry practices evolve and emphasize preventative health measures, the demand for toxoid vaccines is projected to increase, driving growth in this segment of the veterinary vaccines market.

By Application

Livestock Animals:

The livestock animals segment is a significant contributor to the veterinary animal vaccines market, given the increasing global demand for meat, dairy, and other animal products. Vaccination is crucial in protecting livestock from highly contagious diseases, ensuring animal welfare, and maintaining food safety standards. Diseases such as bovine respiratory disease, porcine reproductive and respiratory syndrome, and Newcastle disease pose significant threats to livestock health and productivity. As farmers strive to meet the growing demand for animal protein, the emphasis on herd health management through vaccination is paramount. Consequently, state and federal regulations mandating vaccination protocols for livestock are also driving market growth in this segment, encouraging producers to invest in effective vaccination programs.

Companion Animals:

The companion animals segment is increasingly gaining attention due to the rising trend of pet ownership worldwide. As pet owners become more aware of the importance of preventive healthcare, the demand for veterinary vaccines for dogs, cats, and other pets is growing. Vaccines for diseases such as parvovirus, rabies, and feline leukemia are crucial for ensuring the health and longevity of companion animals. Additionally, the growing inclination towards responsible pet ownership is driving the adoption of routine vaccination schedules, which in turn, boosts the veterinary vaccines market. The segment's growth is further supported by veterinary recommendations and awareness campaigns that emphasize the significance of vaccinations in preventing outbreaks of infectious diseases among pets.

Wildlife Animals:

The wildlife animals segment of the veterinary vaccines market is relatively niche but has been gaining traction due to increasing concerns about biodiversity and wildlife health. Vaccination programs for wildlife are aimed at controlling disease outbreaks that can affect populations of wild animals, and also prevent the transmission of zoonotic diseases to domestic animals and humans. Diseases such as rabies and canine distemper virus have been addressed through vaccination initiatives in various regions. With increasing funding and initiatives from conservation organizations and government agencies to protect wildlife, the vaccination of wildlife animals is expected to grow, driven by the desire to maintain ecological balance and protect endangered species.

By Distribution Channel

Veterinary Hospitals:

Veterinary hospitals play a critical role in the distribution of veterinary vaccines, serving as primary healthcare facilities for pets and livestock. These establishments are often equipped with experienced veterinary professionals who administer vaccines, manage vaccination schedules, and provide follow-up care. The presence of veterinary hospitals assures pet owners and livestock farmers of proper vaccine handling and administration, which is essential for ensuring vaccine efficacy and safety. Furthermore, many veterinary hospitals are increasingly offering vaccination services at competitive prices, thus contributing to the growing demand for vaccines through this channel. With the rise in pet ownership and livestock farming, veterinary hospitals are expected to remain a significant distribution channel, promoting responsible vaccination practices.

Veterinary Clinics:

Veterinary clinics serve as a primary point of care for companion animals and provide a convenient option for pet owners to access vaccination services. These clinics typically offer a wide range of veterinary services, including preventative care, diagnostics, and vaccinations. The growing trend of routine vaccinations for pets is significantly bolstering the market presence of veterinary clinics. As more pet owners recognize the importance of maintaining their pets' health through vaccines, the preference for veterinary clinics is expected to grow. Additionally, the ability of clinics to cater to local communities enhances their role as important distribution channels for veterinary vaccines, especially in urban areas where pet ownership is high.

Veterinary Research Institutes:

Veterinary research institutes are pivotal in the development and distribution of innovative vaccines. These institutes engage in extensive research and trials to create and validate new vaccine formulations, ensuring they are effective against various diseases impacting animal health. The collaboration between research institutes and veterinary practitioners accelerates the adoption of new vaccines in the market. The increasing focus on research and development in veterinary medicine is driving the growth of this distribution channel, as these institutes continue to spearhead initiatives aimed at improving vaccine efficacy and safety profiles. Furthermore, they often provide training and resources to veterinary professionals, thereby enhancing the overall vaccination landscape.

Online Pharmacies:

The emergence of online pharmacies has transformed the distribution landscape of veterinary vaccines, providing pet owners and livestock farmers with greater accessibility and convenience. These platforms allow customers to order vaccines from the comfort of their homes and often provide competitive pricing compared to traditional distribution channels. Online pharmacies enable rural and remote populations, who may have limited access to veterinary clinics and hospitals, to procure essential vaccines for their animals. The growth of e-commerce and digital health platforms is expected to continue driving the popularity of online pharmacies in the veterinary sector, significantly impacting how vaccines are distributed and accessed.

Others:

Other distribution channels include numerous outlets such as agricultural cooperatives, feed stores, and independent retailers. These channels cater primarily to rural and farming communities, providing additional access points for veterinary vaccines. The convenience of purchasing vaccines alongside feed and other farming supplies makes them attractive options for livestock owners. These outlets often provide education and guidance on proper vaccination practices, contributing to informed purchasing decisions among farmers. As awareness about animal health continues to rise, these alternative distribution channels are expected to play an increasingly significant role in the veterinary vaccines market, especially in regions with a high concentration of livestock farming.

By Technology

Conjugate Vaccines:

Conjugate vaccines represent an innovative approach in vaccine technology, combining polysaccharide antigens from pathogens with carrier proteins to enhance the immune response. This technology has been particularly effective in targeting bacteria responsible for diseases such as Streptococcus pneumoniae and Haemophilus influenzae. In the veterinary sector, conjugate vaccines are gradually gaining traction, particularly for preventing bacterial infections in livestock and companion animals. Their ability to provide long-lasting immunity with fewer doses makes them an attractive option for veterinarians and animal owners alike. As research continues to unlock the potential of conjugate vaccines for various diseases, their adoption is expected to expand, contributing to the overall growth of the veterinary animal vaccines market.

Inactivated and Subunit Vaccines:

Inactivated and subunit vaccines utilize killed pathogens or specific proteins from pathogens to stimulate an immune response. These vaccines are widely used in veterinary medicine due to their safety profiles and effectiveness in preventing diseases in various animal species. Inactivated vaccines are particularly prevalent in livestock for controlling viral and bacterial infections, while subunit vaccines are gaining popularity for companion animals. The increasing awareness of the importance of vaccination for disease prevention has led to a surge in demand for these types of vaccines, prompting manufacturers to focus on the development of more effective formulations. The ongoing research on optimizing inactivated and subunit vaccines is expected to further drive their adoption, enhancing the market's growth prospects.

Recombinant Vaccines:

Recombinant vaccines represent a significant advancement in veterinary medicine, leveraging genetic engineering techniques to create targeted vaccines against specific diseases. By utilizing pieces of the pathogen's genetic material, these vaccines can stimulate a robust immune response without the risk of disease. Recombinant vaccines are being increasingly utilized in the prevention of viral infections in livestock and companion animals due to their high efficacy and safety. The ongoing development of new recombinant vaccines tailored to emerging diseases is expected to bolster their market share. Additionally, the benefits of recombinant vaccines, including their ability to provide long-lasting immunity and the potential for reduced production costs, make them a promising segment within the veterinary animal vaccines market.

By Region

The North American region is a leading market for veterinary animal vaccines, driven by the high levels of pet ownership and extensive livestock farming. The growing awareness of animal health and welfare, along with regulatory frameworks that mandate vaccinations for livestock, is significantly boosting the market in this region. The North American veterinary vaccines market accounted for approximately USD 2.5 billion in 2025 and is expected to grow at a CAGR of 5.8% through 2035, propelled by increasing investments in animal health by both private and public sectors. The established veterinary healthcare infrastructure and the presence of key players in the region further favor the growth dynamics of the veterinary vaccines market.

In Europe, the veterinary animal vaccines market is also witnessing considerable growth, attributed to stringent regulations concerning animal health and welfare. The European market was valued at USD 1.8 billion in 2025 and is projected to grow at a CAGR of 5.5% until 2035. Countries such as Germany, France, and the UK exhibit high pet ownership rates, driving demand for companion animal vaccines. Furthermore, the emphasis on surveillance and control of zoonotic diseases underpins the European Union's policies, ensuring a proactive approach towards vaccination. The increasing adoption of innovative vaccine technologies and heightened awareness of animal health issues are also contributing factors to the positive growth outlook in the European veterinary vaccines market.

Opportunities

One of the significant opportunities in the veterinary animal vaccines market lies in the growing trend of personalized medicine, which emphasizes customized vaccination protocols based on individual animal health needs. As veterinary practices advance, the ability to tailor vaccines to specific breeds, age groups, or health conditions presents a unique opportunity for vaccine developers. This personalization can enhance vaccination efficacy and improve overall animal health outcomes. Moreover, the rise in zoonotic diseases and the increasing public awareness of animal health can drive demand for innovative and specialized vaccines targeting these emerging threats. As veterinarians increasingly adopt a tailored approach to healthcare, the potential market for personalized veterinary vaccines is likely to expand, fostering innovation and further investment in research and development.

Additionally, the increasing adoption of digital technologies in veterinary medicine, such as telemedicine and online health platforms, presents new opportunities for the veterinary vaccines market. These technologies facilitate better access to veterinary care, allowing more pet owners and livestock farmers to obtain timely vaccinations. The establishment of online pharmacies and telehealth consultations can streamline vaccination processes, ensuring compliance with vaccination schedules and enhancing animal well-being. Furthermore, digital platforms can provide valuable resources and information to pet owners and farmers on the importance of vaccinations, thus fostering a more proactive approach to animal health. This convergence of technology and veterinary care is expected to create significant market opportunities in the coming years.

Threats

Despite the positive outlook for the veterinary animal vaccines market, several threats could hinder its growth. One of the primary concerns is the rising prevalence of anti-vaccine sentiments among pet owners, which can lead to reduced vaccination rates and pose a risk to both animal and public health. The spread of misinformation regarding the safety and efficacy of vaccines, particularly on social media platforms, can exacerbate this issue. Additionally, the emergence of new diseases and pathogens that may not be adequately addressed by existing vaccines poses a significant challenge. As pathogens evolve, there is a continuous need for research and development to keep pace with emerging health threats, which can strain resources and lead to increased costs for vaccine manufacturers.

Another critical threat to the veterinary vaccines market is the increasing regulatory scrutiny on vaccine development and approval processes. Stricter regulations aimed at ensuring vaccine safety and efficacy could lead to delays in bringing new products to market and increase the overall cost of research and development. This could particularly impact smaller companies and startups that may lack the resources to navigate complex regulatory environments. Additionally, the ongoing impacts of economic fluctuations and trade restrictions can affect the supply chain for vaccine components, ultimately leading to potential vaccine shortages in certain regions. These threats necessitate careful consideration and strategic planning from stakeholders within the veterinary vaccines market.

Competitor Outlook

• Zoetis Inc.
• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Ceva Sante Animale
• Heska Corporation
• Virbac
• Vetoquinol S.A.
• Merial S.A.S. (part of Boehringer Ingelheim)
• Hipra
• Neogen Corporation
• Agrovet Market Animal Health
• Phibro Animal Health Corporation
• Sangster & Sons Ltd.
• Vaxxinova

The veterinary animal vaccines market is characterized by a competitive landscape comprising several established players that dominate the industry. Companies like Zoetis Inc., Merck Animal Health, and Boehringer Ingelheim are at the forefront, leveraging their extensive research and development capabilities to innovate and offer a broad range of vaccine solutions. These market leaders maintain robust distribution networks and have established partnerships with veterinary clinics, hospitals, and research institutes, enabling them to penetrate diverse markets effectively. Furthermore, the emphasis on product differentiation and the introduction of novel vaccine formulations have become key strategies for maintaining market dominance amidst increasing competition.

Zoetis Inc., for instance, is a leading player in the veterinary vaccines market, offering a comprehensive portfolio of vaccines for livestock and companion animals. The company's investments in research and development have resulted in the introduction of innovative products that address emerging health threats. Moreover, their focus on building strong relationships with veterinarians and animal health professionals has enhanced their market presence. Similarly, Merck Animal Health continues to invest significantly in vaccine development and has a well-diversified product line that caters to various species, including cattle, poultry, and pets.

Another notable player, Boehringer Ingelheim, has made significant strides in the veterinary vaccines sector, emphasizing the importance of research and development in creating effective vaccine solutions. The company’s commitment to animal welfare and public health has positioned it as a trusted provider of veterinary vaccines. Additionally, their global reach and extensive distribution channels allow them to deliver vaccines to diverse markets effectively. As the veterinary animal vaccines market continues to evolve, these key players are expected to remain influential, driving innovation and competition within the industry.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Hipra
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Virbac
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Vaxxinova
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Zoetis Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Vetoquinol S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Heska Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Ceva Sante Animale
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Neogen Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck Animal Health
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Boehringer Ingelheim
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Elanco Animal Health
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Sangster & Sons Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Agrovet Market Animal Health
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Phibro Animal Health Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Merial S.A.S. (part of Boehringer Ingelheim)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Veterinary Animal Vaccines Market, By Technology
    • 6.1.1 Conjugate Vaccines
    • 6.1.2 Inactivated and Subunit Vaccines
    • 6.1.3 Recombinant Vaccines
  • 6.2 Veterinary Animal Vaccines Market, By Application
    • 6.2.1 Livestock Animals
    • 6.2.2 Companion Animals
    • 6.2.3 Wildlife Animals
  • 6.3 Veterinary Animal Vaccines Market, By Product Type
    • 6.3.1 Inactivated Vaccines
    • 6.3.2 Live Attenuated Vaccines
    • 6.3.3 Recombinant Vaccines
    • 6.3.4 DNA Vaccines
    • 6.3.5 Toxoid Vaccines
  • 6.4 Veterinary Animal Vaccines Market, By Distribution Channel
    • 6.4.1 Veterinary Hospitals
    • 6.4.2 Veterinary Clinics
    • 6.4.3 Veterinary Research Institutes
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Veterinary Animal Vaccines Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Veterinary Animal Vaccines market is categorized based on

By Product Type

• Inactivated Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• DNA Vaccines
• Toxoid Vaccines

By Application

• Livestock Animals
• Companion Animals
• Wildlife Animals

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Veterinary Research Institutes
• Online Pharmacies
• Others

By Technology

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Recombinant Vaccines

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Zoetis Inc.
• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Ceva Sante Animale
• Heska Corporation
• Virbac
• Vetoquinol S.A.
• Merial S.A.S. (part of Boehringer Ingelheim)
• Hipra
• Neogen Corporation
• Agrovet Market Animal Health
• Phibro Animal Health Corporation
• Sangster & Sons Ltd.
• Vaxxinova